David Francis Carroll - 21 Apr 2023 Form 4 Insider Report for IVERIC bio, Inc.

Role
SVP, Chief Financial Officer
Signature
/s/ Todd D.C. Anderman, as Attorney-in-Fact for David Carroll
Issuer symbol
N/A
Transactions as of
21 Apr 2023
Net transactions value
-$1,510,116
Form type
4
Filing time
25 Apr 2023, 19:27:20 UTC
Previous filing
04 Jan 2023
Next filing
03 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ISEE Common Stock Options Exercise $2,652 +1,829 +2.7% $1.45* 70,301 21 Apr 2023 Direct F1
transaction ISEE Common Stock Sale $54,870 -1,829 -2.6% $30.00 68,472 21 Apr 2023 Direct F1, F2
transaction ISEE Common Stock Options Exercise $69,848 +48,171 +70% $1.45* 116,643 24 Apr 2023 Direct F1
transaction ISEE Common Stock Sale $1,455,246 -48,171 -41% $30.21 68,472 24 Apr 2023 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ISEE Stock Option (right to buy) Options Exercise $2,652 -1,829 -3.7% $1.45* 48,171 21 Apr 2023 Common Stock 1,829 $1.45 Direct F1, F4
transaction ISEE Stock Option (right to buy) Options Exercise $69,848 -48,171 -100% $1.45* 0 24 Apr 2023 Common Stock 48,171 $1.45 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 16, 2022.
F2 The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at a price of $30.00 per share on April 21, 2023. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range.
F3 The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from $30.00 to $30.51 per share on April 24, 2023. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range.
F4 This stock option award was granted on December 12, 2018 and vested with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in approximately equal monthly installments through the fourth anniversary of the grant date.